Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
121 hedge funds and large institutions have $392M invested in Esperion Therapeutics in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 54 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
14% more call options, than puts
Call options by funds: $13.8M | Put options by funds: $12.1M
20% less funds holding
Funds holding: 151 → 121 (-30)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
54% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 54
72% less capital invested
Capital invested by funds: $1.39B → $392M (-$994M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$57M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$32.9M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$28.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$114M |
| 2 |
VAM
Visium Asset Management
New York
|
-$64.7M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$51.1M |
| 4 |
Two Sigma Investments
New York
|
-$22.4M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$12.6M |
ESPR Hedge Fund Activity: Q3 2015 in Review
121 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2015, worth a combined $392M — down 72% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of ESPR and 25 opened new positions — a net loss of 29 holders — while 31 trimmed existing stakes and 51 added.
The largest buyer was BB Biotech, opening a new position worth an estimated $57M. The largest seller was Viking Global Investors, exiting entirely with an estimated $114M sold.
- 121 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2015, down from 151 in Q2 2015.
- Funds reported $392M of Esperion Therapeutics stock for Q3 2015, down 72% quarter-over-quarter.
- 25 funds opened new Esperion Therapeutics positions in Q3 2015 and 54 closed out, a net change of -29 holders.
- The largest Esperion Therapeutics buyer in Q3 2015 was BB Biotech, an estimated $57M added.
- The largest Esperion Therapeutics seller in Q3 2015 was Viking Global Investors, an estimated $114M sold.
Based on aggregated 13F filings for Q3 2015.